title: Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus.
abstract: At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results. A phase III HSCT trial is being developed to confirm efficacy of HSCT vs continuing the currently accepted standard of care, intravenous pulse cyclophosphamide.
authors.affiliation: Northwestern University Medical Center, Chicago, IL 60611, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Burt
authors.forename: A
authors.initials: A
authors.lastname: Marmont
authors.forename: R
authors.initials: R
authors.lastname: Arnold
authors.forename: F
authors.initials: F
authors.lastname: Heipe
authors.forename: G S
authors.initials: GS
authors.lastname: Firestein
authors.forename: E
authors.initials: E
authors.lastname: Carrier
authors.forename: B
authors.initials: B
authors.lastname: Hahn
authors.forename: W
authors.initials: W
authors.lastname: Barr
authors.forename: Y
authors.initials: Y
authors.lastname: Oyama
authors.forename: J
authors.initials: J
authors.lastname: Snowden
authors.forename: K
authors.initials: K
authors.lastname: Kalunian
authors.forename: A
authors.initials: A
authors.lastname: Traynor
mesh_terms: D002985:Clinical Protocols; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000401:mortality / Q000628:therapy*; D012720:Severity of Illness Index; D019172:Transplantation Conditioning / Q000379:methods